The Maryland Court of Appeals has ruled, 6-1, that the off-label use of drugs is not relevant evidence in lawsuits in which plaintiffs allege their doctors failed to obtain their informed consent.

Judge Lynne Battaglia, writing for the majority, said the regulatory status of a drug is not material information that a patient needs to know before giving informed consent to treatment.